This past December, VBI Vaccines announced it had initiated two parallel Phase III trials of their hepatitis B vaccine, Sci-B-Vac (hepatitis B [virus-like particle] vaccine), in head-to-head studies against GlaxoSmithKline’s (GSK’s) Engerix-B (hepatitis B vaccine [recombinant]), with the goal of justifying regulatory approval in the US, EU, and Canada.

Even if VBI is able to demonstrate Sci-B-Vac’s superior efficacy compared with Engerix-B, GlobalData expects the firm will have to face off against Dynavax Technology’s Heplisav-B (hepatitis B vaccine [recombinant], adjuvanted),  which received FDA approval in November 2017 and will have a clear head start in penetrating the US marketplace.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sci-B-Vac consists of all three surface antigens of the hepatitis B virus (HBV): the S antigen, which is the primary antigenic component of all hepatitis B vaccines currently approved in the US, EU, and Canada, plus the pre-S1 and pre-S2 surface antigens. The vaccine elicits protection by delivering these antigens as enveloped virus-like particles (eVLPs), which mimic the size and structure of the HBV.

A previously completed head-to-head Phase III trial demonstrated 96.6%  and 96.0% seroprotection following three doses of Sci-B-Vac in those ≤45 and >45 years old, respectively, compared with 86.0% and 78.6% seroprotection provided by three doses of Engerix-B. These results justified regulatory approval in Israel and 14 other countries.

If Sci-B-Vac is approved it will face serious competition from Dynavax Technology’s Heplisav-B (hepatitis B vaccine [recombinant], adjuvanted), which was approved in November 2017. Heplisav-B boasts a high seroprotection rate, ranging from 91.6–100% across all age groups following only two doses delivered one month apart.

VBI vaccines’ CEO has said that they might pursue approval for Sci-B-Vac as a two-dose regimen, but from the published Phase III results, seroprotection following two doses was found to only be 34.7%, and therefore it seems unlikely to be able to compete with the efficacy of Heplisav-B in just two doses. VBI Vaccines has also failed to include efficacy following two doses as a primary endpoint in either of the company’s new trials, so approval for a two-dose regimen seems unlikely at this point.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData believes that VBI Vaccines should consider altering the design of Phase III trials for Sci-B-Vac to include a more focused investigation into a two-dose regimen. However, Dynavax had a tough time when seeking approval for Heplisav-B due to its proprietary adjuvant contained in the vaccine, so marketing Sci-B-Vac as an adjuvant-free vaccine could remain an option to VBI Vaccines if it ends up going against Heplisav-B with a three-dose vaccine.